news
New data show Striverdi® (olodaterol)* Respimat® improves exercise tolerance in patients with moderate to very severe COPD
29 October 2013 | By Boehringer Ingelheim
“Exercise is an essential component of COPD management..."
List view / Grid view
Boehringer Ingelheim
news
Global Lung Cancer Coalition to identify patient challenges and improve support strategies in partnership with Boehringer Ingelheim
28 October 2013 | By Boehringer Ingelheim
'Lung Cancer: We're Listening' will gather much needed feedback from individuals touched by lung cancer...
news
New efficacy and safety data adds to evidence suppoith afatinib*(GIOTRIF®) in Asian and non-Asian lung cancer patients
27 October 2013 | By Boehringer Ingelheim
"The new sub-analysis confirms the consistent safety profile of afatinib in Asian patients..."
news
New once-daily Striverdi* (olodaterol) Respimat® gains approval in first EU countries
18 October 2013 | By Boehringer Ingelheim
"The improvements in lung function and quality of life seen with once-daily Striverdi® Respimat® are remarkable..."
news
Boehringer Ingelheim submits nintedanib*, a novel oncology compound, for European approval
14 October 2013 | By Boehringer Ingelheim
Nintedanib*, when added to chemotherapy, is the first lung cancer treatment that extended patient survival...
news
Investigational interferon-free regimen demonstrates undetectable hepatitis C virus in all patients reaching end of treatment in ongoing Phase II trial
8 October 2013 | By Boehringer Ingelheim
"These results are promising particularly because they show the potential to evaluate harder-to-treat populations..."
news
Ben Venue Laboratories, Inc. to cease production
7 October 2013 | By Boehringer Ingelheim Corp
Ben Venue Laboratories, Inc has decided to cease production by the end of 2013...
news
Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa® compared to warfarin
Anticoagulants are an indispensable treatment to prevent dangerous blood clots that can cause devastating ischaemic strokes in patients with atrial fibrillation or life-threatening pulmonary embolism in patients with venous thromboembolism.1,2 An increased risk of bleeding is a known possible complication of all anticoagulant therapies.3 This research shows that applying existing…
news
Nintedanib extended survival beyond one year for advanced adenocarcinoma patients after prior first-line chemotherapy
30 September 2013 | By Boehringer Ingelheim
LUME-Lung 1 Phase III clinical trial showed that the novel investigational compound nintedanib* provided a significant and clinically relevant overall survival benefit for advanced non-small cell lung cancer...
news
Boehringer Ingelheim Animal Health achieves milestone: 500 million pigs benefit from Mycoplasma vaccination
27 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced today that veterinarians and farmers across the globe have reached the milestone of protecting more than 500 million pigs from the potentially devastating consequences of Mycoplasma hyopneumonia...
news
Boehringer Ingelheim expands its production footprint in China
27 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim has inaugurated the building of its chemicals R&D laboratory Center of Competence in the Zhangjiang High-Tech Park in Shanghai...
news
Data presented at EASD support safety profile of Trajenta® (linagliptin) in broad range of adults with Type 2 Diabetes
24 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced that results from two different pooled analyses of clinical studies support previous observations that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin was shown to be well tolerated in a broad range of adults with Type 2 Diabetes (T2D). These data were presented…
news
Ventana to collaborate with Boehringer Ingelheim on the development of companion diagnostic tests
19 September 2013 | By Boehringer Ingelheim
Companies collaborate on the development of companion diagnostic tests for Boehringer Ingelheim Oncology programmes...
news
Volasertib receives FDA Breakthrough Therapy designation for treatment of patients with acute myeloid leukaemia
17 September 2013 | By Boehringer Ingelheim
Administration (FDA) to potentially provide a new treatment option to improve survival related outcomes for patients with acute myeloid leukaemia (AML)...
news
Boehringer Ingelheim broadens efforts for interferon-free hepatitis C treatments through clinical collaboration with Presidio Pharmaceuticals
10 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced the completion of patient enrolment for a Phase IIa clinical trial...
